Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P. May 15, 2025 04:59PM
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P. Feb 14, 2025 06:42PM
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P. Nov 14, 2024 05:46PM
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P. Feb 14, 2024 05:02PM
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P. Aug 1, 2023 04:31PM


Nov 23, 2022 08:03AM NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential